576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study.
Saved in:
| Title: | 576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study. |
|---|---|
| Authors: | Gong, J.1 (AUTHOR), Lemech, C.2 (AUTHOR), Day, D.3 (AUTHOR), Shan, J.4 (AUTHOR), Morris, M.5 (AUTHOR), Nagrial, A.6 (AUTHOR), Chen, M.7 (AUTHOR), Huang, X.8 (AUTHOR), Zong, H.9 (AUTHOR), Wang, N.10 (AUTHOR), Yang, Y.11 (AUTHOR), Yi, T.12 (AUTHOR), Li, W.13 (AUTHOR), Zhuang, Z.14 (AUTHOR), Li, Z.15 (AUTHOR), Liu, Z.16 (AUTHOR), Luo, Y.17 (AUTHOR), Zhang, Y.17 (AUTHOR), Zhou, H.17 (AUTHOR), Shen, L.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS467-S468. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.645 |
